Targeting EGFR in Triple Negative Breast Cancer

Related Experiment Video

Updated: May 31, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Naoto T Ueno1, Dongwei Zhang

  • 11. Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Journal of Cancer
|July 1, 2011
PubMed

Insights

Erlotinib shows preliminary effectiveness against triple-negative breast cancer (TNBC) in models. However, its metastasis inhibition has nonspecific effects, necessitating the identification of direct targets for better TNBC therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted therapy options.
  • Erlotinib, a tyrosine kinase inhibitor, has shown preliminary efficacy in TNBC models.
  • Metastasis remains a significant challenge in TNBC treatment, and erlotinib's effects on it require further investigation.

Purpose of the Study:

  • To evaluate the inhibitory effects of erlotinib on TNBC metastasis in a xenograft model.
  • To investigate the specificity of erlotinib's antimetastatic activity.
  • To identify direct molecular targets regulating TNBC metastasis for improved therapeutic strategies.

Main Methods:

  • Utilized a TNBC xenograft mouse model to assess erlotinib's efficacy.
  • Analyzed erlotinib's effects on tumor growth and metastasis.
  • Investigated potential off-target kinase inhibition by erlotinib.

Main Results:

  • Preliminary data indicate that erlotinib inhibits TNBC in the xenograft model.
  • Erlotinib's inhibition of metastasis was associated with nonspecific effects.
  • The drug's broad kinase inhibition profile suggests potential off-target activities impacting metastasis.

Conclusions:

  • Erlotinib demonstrates preliminary anticancer activity in TNBC models.
  • The nonspecific effects of erlotinib on metastasis highlight the need for target-specific approaches.
  • Identifying direct targets is crucial for enhancing the therapeutic efficacy of TNBC treatments.
Keywords:
EGFRerlotinibmetastasistriple negative breast cancertyrosine kinase inhibitor

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...